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Summary 
Background: Extracts of Hypericum perforatum have demon­
strated in randomized trials (RCTs) to be effective in mild to 
moderate depressive episodes, However, as their use in daily 
practice may differ from that in RCTs we have conducted a 
study to achieve a better estimate of the range and frequency 
of adverse drug reactions (ADR) and the efficacy. Patients 
and Methods: In an observational study in Germany, adult 
outpatients with depressive syndrome were treated with an 
extract of St. John's Wort. Study duration was 12 weeks, with 
control visits every 4 weeks, Besides anamnestic data, the 
variables assessed were: evolution of ICD-l0 derived symp­
\Dm score, Global Clinical Impression scale (GCI) , and tolera­
oility, Results: 1,778 patients from 304 centers participated in 
the study (mean duration of disorder 7.3 ± 18.9 months), and 
1,541 patients completed it. At the last control visit the ICD-l0 
sum score had dropped by 63.1 % and the proportion of pa­
tients described as 'normal to mildly ill' (GCI-s) had increased 
from 21 .6% at admission to 72.4%. Regarding the GCI-i, 77% 
of the patients had improved 'very much' or 'much' at the last 
v isit. This was consistent with their self-assessment (76%). 
Lower age and shorter duration of the disorder were associ­
ated with significantly better outcomes, The incidence of 
ADRs was 3,54% and had been decreasing continuously fram 
the first contra I visit onwards; serious ADRs did not occure, 
Conclusions: The herbai drug was weil tolerated, and no new 
or serious ADR were identified. In view of the limitations in­
herent to the study design, it can be concluded that extracts 
of St. John's Wort are effective as an antidepressant in the 
management of depression in daily practice. 
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Zusammenfassung 

Hintergrund: In randomisierten Studien (RCT) zeigen sich Jo­

hanniskrautextrakte in der Behandlung von Patienten mit mil­

den bis mäßigen depressiven Episoden als wirksam. Da sich 

die Anwendung in der ärztlichen Alltagspraxis jedoch von 

RCTs unterscheiden kann, führten wir eine Studie durch, um 

Spektrum und Häufigkeit unerwünschter Arzneimittelwirkun­

gen (UAW) sowie Aspekte der Wirksamkeit besser abschätzen 

zu können. Patienten und Methode: In einer offenen Studie in 

Deutschland wurden erwachsene Patienten, die an einem de­

pressiven Syndrom litten, 12 Wochen lang (mit 4-wöchent­

lichen Kontrolluntersuchungen) ambulant mit einem Johan­

niskrautextrakt behandelt. Neben den anamnestischen Daten 

wurden folgende Variablen untersucht: ICD-l0-basierter Sym­

ptomscore, Global Clinical Impression Scale (GCI) , Verträg­

lichkeit. Ergebnis: 1778 Patienten aus 304 Arztpraxen nahmen 

an der Studie teil (durchschnittliche Krankheitsdauer 7,3 ± 

18,9 Monate) und 1541 beendeten die Studie. Bei der letzten 

Kontrolluntersuchung war der ICD-l0-Summenscore um 

63,1 % gesunken . Der Anteil der Patienten, die sich als «nor­

mal bis leicht krank» (GCI-s) einstuften, war von 21,6% zu Be­

ginn auf 72,4% am Ende der Studie gestiegen. Bezogen auf 

die GCI-i ging es 77% Patienten am Ende «sehr viel» oder 

«viel» besser, was mit der Selbsteinschätzung der Patienten 

(76%) gut übereinstimmte. Ein niedrigeres Alter und eine kür­

zere Erkrankungsdauer waren mit einem signifikant besseren 

Outcome verbunden. Die Inzidenz von UAW betrug 3,54% 

und nahm von der ersten Kontrolluntersuchung an kontinuier­

lich ab; schwerwiegende UAWs wurden nicht beobachtet. 

Schlussfolgerung: Das pflanzliche Medikament wurde gut 

vertragen; es wurden keine neuen oder schwerwiegenden 

UAW berichtet. Vor dem Hintergrund der Einschränkungen 

durch das Studiendesign kann die Intervention als wirksam in 

der Behandlung von Patienten mit Depressionen in der AII­

tagspraxis angesehen werden. 
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Background 
Depression is associated with significant social and functional 
impairments as weil as high direct and indirect health care 
costs [1 , 2]. Depressive disorders have been reported to cause 
even greater functional disability than diabetes, chronic lung 
disease, hypertension, or back pain [3]. Depressive disorder is 
a chronic disorder which is often characterized by relapses 
and recurrences. The lifetime risk of depression is 10-25% for 
women and 5-12% for men [4,5]. Furthermore, epidemiologi­
cal data suggest that 75-80% of patients experience recurrent 
depression. The rate and timing of recurrence mainly seems 
to depend on the type of recovery. In patients who recovered 
completely the rate of recurrence was much lower and the 
time to recurrence was much longer than in patients with re­
sidual symptoms [6]. 
Recent research in a setting comparable to daily practice 
has demonstrated that about 50% of patients respond to the 
first antidepressive monotherapy but only about 30% achieve 
remission [7] . The rate of remission can be increased to al­
most 50% when a second drug is used if the initial antidepres­
sant drug fails. With an ongoing sequential monotherapy, with 
a change to a third or fourth drug, remission can be improved 
by an additional 10% each time [5]. However, in placebo-con­
trolled trials high relapse rates of 40-60% were observed 
within 6 mdnths after discontinuation of the antidepressant 
treatment [8, 9]. Therefore, further treatment strategies and 
more effective or better tolerated agents continue to be re­
quired in order to improve treatment outcomes in all 3 phases 
of depression management commonly accepted: (1) acute 
phase, usually 6-12 weeks; (2) continuation phase, in which 
the goal of the treatment is to maintain the absence of depres­
sive symptoms for an additional 4-9 months so that the de­
pressive episode can be considered completeJy resolved; and 
(3) maintenance phase, i.e. often several years during which 
the goal of the treatment is to prevent the recurrence of an­
other distinct depressive episode. 
The goal of treatment is to achieve full remission of symp­
toms, which may take up to 4 months, and to maintain remis­
sion. To this end, according to current guideJines the antide­
pressant to be given should be matched to the individual pa­
tient's requirements considering [10, 11]: 
- previous treatment response to a particular drug, 
- tolerability and adverse effects of a previously given drug, 
- profile of side effects (e.g. sedation, weight gain), 
- low lethality, if history or likelihood of overdose, 
- concurrent physical illness or condition that may make the 
antidepressant more noxious or less tolerated , 
- concurrent medication that may interact with the antide­
pressant drug, 
- associated psychiatrie disorder that may specifically re­
spond to a particular dass of antidepressant (e.g. obsessive 
compulsive disorder and serotonin reuptake inhibitors), 
- patients' preference. 
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The study presented here is an open, descriptive, observa­
tional (case series) study with a proprietary e thanolic extract 
of Hypericum perforaturn, conducted under conditions of 
daily practice in Germany. The scope of such studies is to ob­
ta in information on prescription modalities, acceptability . 
compliance of the medication, achieve a bett er estimate of the 
frequency of adverse effects (and possibly identify rare, hith­
erto unknown adverse reactions) and get a broader picture of 
the efficacy (e.g. inclusion of subgroups not studied in earlier 
trials) [12]. 
Patients and Methods 
Study Design and Variables 
Patients with depressive disorders were trea ted with a herbai preparation 
of Hypericum perforaturn (Helarium"', Bionorica AG, Neumarkt. Ger­
many) in a community-based outpatient se tting in Germany. Th e physi­
cians participating in this observational multicenter study included gen­
eral practitioners, internists, neurologists, and psychiatrists. The diag­
noses were descriptive in th e wordings of the investigators (treating phy­
sician) and later coded according to ICD-10 (one main term and one 
descriptor term by R.B.). The ICD-derived scales were validated with the 
HAMD17 and its subscores and correlated weil (data presented else­
where). Treatment was documented for adult outpatients with depressive 
symptoms that required a pharmacological intervention. 
Patients with any contraindication for Hypericum, with poor tolerabil­
ity in a previous treatment with Hypericum, or who currently participated 
in a c1inical study were not included in the study. Hypericum dosage was 
initiated according 10 the recommendations in the package insert , but 
could subsequently be adjusted according 10 the physician's estimate re­
garding best balance of efficacy and tolerability. The length of the trial 
was set at 3 monlhs in order to allow sufficient time for a response to con­
solidate and for c1inical benefits 10 be evident. 
Data assessment was performed at 4 times: at baseline and at weeks 4, 
8, and 12 (study termination) , with the idea of identifying adverse drug 
reactions (ADRs) and estimating change of symptoms in terms of early 
response and at study end to see the maximum achieved effect. Demo­
graphics (age, sex, marital and professional status) and psychiatrie hi story 
(duration of current episode, current diagnosis, concomitant di seases and 
medication , prescribed dosage of Hypericum [Helarium® capsules or tab­
lets]) were recorded at the baseline visit (table 1). 
The Clinical Global Impression scale (CGI) was used to evaluate the 
extent of change during treatment with Hypericum , as the CGI can be 
wide ly used in psychiatry [13]. Severity was assessed by the 7-point CGI 
- severity scale (CGI-s; 1 =normal/not at all ill ; 7 =extremely ill) . The 
description of this sca le states that 'the severity of illness item requires the 
c1inician to rate the severity of the patie nl 's illness at the time of assess­
ment , relative to the c1inician 's past experience with patients who have 
the same diagnosis'. 
The extent of improvement was assessed by the 7-point CGI - im­
provement scale (CGI-i; 1 = very much improved; 7 = very much wors.:) 
at the 2nd, 3rd , and final visit. The CG1-i asks the c1inician to rate ho\\ 
much the patient's illness has improved or worsened relative to a bas.: lin c: 
state. A patient's iJlness is compared to change over time and rated ..-\d­
ditionally , Ihe patients also evaluated their status themse lves by emplo\­
ing simplified ve rsions of the CGI-s and the CGI-i. 
ICD-10 criteria were used to construct a severity rating on a sc- k 
from 0 = absent , to 4 = severe; that is: (1) 'depression ' (mood ( aff~c ­
tive) disorders, F30-F39): such as lowering of mood, loss or int Lr~,\. 
lack of energy, reduction of self-esteem ; (2) ' anxiety' (neurolic. sIr <­
related , and somatoform disorders, F40-F44, F48): such as e\c~ , 01 
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Table 1. Patient data at baseline and patient flow 
Patients included, 0 1778 
Sex, n (%) 

-Male 367 (20.9%) 

- Female 1411 (79.1 %) 

Age, years 

-Mean (SO) 49.76 (15.2) 

- Range 18-97 

Mean (SO) time suffcring from disorder, n:t0nths 7.3± 18.9 
Profession, n (%) 1741 (97.9%) 
- Housewife/man 440 (24.7%) 
-Part-time 221 (12.4%) 
-Full-time 611 (34.4%) 
- Retired 314 (17.7%) 
- Unemployed 155 (8.7%) 
Marital status, n (%) 1741 (97.9%) 
- Single 252 (14.2%) 
-Married 1021 (57.4%) 
- Widowed 246 (13.8%) 
- Divorced 222 (12.5%) 
Dropouts, n 237 
- Due to patients requestlwithdrawal of consent 74 
- Termination of treatment before 3rd visit 70 
- Due to inefficacy 53 
- Reason unknown 37 
- Due to advers~ effects (n) 3 
Patients analyzed, n 1541 
Concomitant treatments, n (%) 194 (10.91 %) 
- Antidepressive: tricyclic antidepressants 21 (1.18%) 
-SSRI 17 (0.96%) 
- MAO inhibitors 2(0.11%) 
- Hypericum 0(0%) 
-NaSSA 5 (0.28%) 
- Antipsychotic: neuroleptics 15 (0.84%) 
- Lithium 1 (0.06%) 
- Anxiolytic: herba I 31 (1.74%) 
- Hypnoticlsedative: benzodiazep./ 46 (2.59%) 
Imidazopyridine 
- Hormonal: HRT 10 (0.56%) 
- Cardiac: nitrates 0(0%) 
- Beta-blockers 3 (0.17%) 
- Analgesic: NSAID 14 (0.79%) 
- Varia, not psychopharmaceutical 27 (1.52%) 
- Not pharmaceutical 2 (0.11 %) 
HRT: Hormonal replacement therapy; MAO inhibitor: Monoamine oxi­
dase A inhibitor; NaSSA: Noradrenergic and specific serotonergic anti­
depressant; NSAlD: Non steroidal anti-inflammatory drug; SSRI: Selec­
tive serotonin reuptake inhibitor. 
anxiety and fears; (3) somatic symptoms related to anxiety/depression 
(neurotic, stress-related, and somatoform disorders, F40-F44, F48): 
such as cardiovascular, or digestive, or respiratory, or muscular trou­
bles; (4) somatoform disorders (F45): such as multiple somatic 
troubles , refuses medical diagnoses, continuous suffering due to 
symptoms. 
Hypericum for Depression in Outpatients 
For each block, the sum score and the highest individual score were 
calculated. Furthermore, the patients were administered a visual ana­
logue scale (VAS; ranging from ' I feel very bad ' to ' I feel very weil') with 
lower values indicating better subjective feelings. In addition, current 
treatments, modifications in the dosage of lhe herbai drug, as weil as 
ADRs (mentioned spontaneously or after general question, respectively) , 
were documented at all visits. 
SI. John's Wort (Hypericumper[oralum) 
One of the problems encountered with herbaI extracts, even from SI. 
10hn's wort, is the variation of their compounds between different prepa­
rations [15]. The herbaI drug itself (i.e. the raw material) is a complex 
multicompound [16], and - depending on the extraction method - its ex­
tracts may differ in quantity and qualitiy [17]. However, Hypericum ex­
traxts possess a moderate to high potency to inhibit the reuptake of 
monoamines, serotonin, dopamine, noradrenaline, and the amino-acid 
neurotransmitters GABA and glutamate. Unlike standard reuptake in­
hibitors, Hypericum exerts this reuptake inhibition in a non-competitive 
way by enhancing intracellular Na+-ion concentrations [19]. Recent stud­
ies indicate that SI. 10hn's wort is capable of increasing the in-vivo 
dopamine release [19], appears to increase extracellular dopamine levels 
in the brain [20] and increase plasma concentration of dihydroxypheny­
lacetic acid (DOPAC), the main metabolite of dopamine, possibly by an 
inhibitory effect on dopamine beta-hydroxylase [21]. 
For this study, the extract provided by the manufacturer, was Helar­
ium Hypericum®, a hypericum extract with 255-285 mg dry ethanolic 
exlract per coated tablet, standardized to hypericin 0.3% and of a hyper­
forin content of 2-3%, or Helarium-425® with 425 mg dry ethanolic ex­
tract per capsule (DER 3.5-6:1). Helarium-425® is slandardized to hyper­
icin 0.1 - 0.3% and has a hyperforin content of max. 6%, flavonoid/ 
rutoside min. 6% in the extract. 
Statistical Methods 
Statistical analysis was performed with WinST AT 2001.1 for Windows 
(SPSS-validated). The continuous data are presenled as means and stand­
ard devialions (SO); additionally, medians, 95% confidence intervals 
(CIs) as weil as ranges, and numbers (n) of patients were calculated. Cat­
egorical data are presented using counts (n) and percentages rounded to 1 
decimal place. All p values are 2-tailed , and p < 0.05 was considered sta­
tistically significant. Unless stated otherwise, values before versus after 
treatment were compared by means of the Student's t-test, or the x'-test 
for nominal or ordinal data. The safety population, defined as subjects 
who received ~1 dose of any study drug and for whom post-dose data 
were available , were used in the analysis and evaluation of the safety 
variables. 
The influence of demographic factors (age, duration of disorder, gen­
der) and the ICD-lO derived score at admission and at the final visit were 
examined by multiple stepwise regression analyses. 
Results 
Demographies and Data at Admission 
304 centers participated in this study with a total of 1,778 pa­
tients (1-17 patients per center), recruited during winter and 
spring 1999. The (cumulative) number of dropouts was 38 at 
visit 1 (after 28.1 ± 30.2 days), 115 at visit 2 (after 57.6 ± 32.7 
days), and 237 patients at visit 3 (after 89.8 ± 36.6 days; table 
1). Questioned about it, 810 patients (45.6%) reported having 
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Table 2. CGI-s at 
CGI 	 Visit Q Visit 1 Visit 2 Visit 3 Last visit LOCF 
admission , at each 
control visit and Normal (not at all iU) 
LOCF (LOCF vs. ad- Borderline mentally ill 
mission, p < 0.001) Mildlyill 
Moderately ill 
Markedly ill 
Severely iU 
Extremely ill 
14(0,8% ) 
88 (4,9%) 
282 (15,8%) 
607 (34%) 
616 (34,5%) 
133 (7,5%) 
6 (0,3 %) 
28 (1,6%) 

98(5,5 %) 

405 (22,7%) 

650 (36,4 %) 

475 (26,6%) 

63 (3,5 %) 

4 (0,2%) 

92 (5,2 %) 
156 (8,7%) 
649 (36,4%) 
525 (29,4%) 
191 (10,7%) 
24 (1,3%) 
1(0,1 %) 
275 (15,4 %) 296 (16,6%) 
191 (10,7 %) 214 (12 %) 
690 (38,7%) 769 (43,1 %) 
257 (14,4%) 310 (17,4%) 
86 (4,8 %) 130(7,3%) 
15 (0,8 %) 25 (1,4%) 
0(0%) 0(0%) 
N =1784 1757 (98,5%) 1740 (97,5%) 1652 (92,6%) 1527 (85,6%) 1757 (98,5%) 
Not assessable 11 (0,6%) 17 (1 %) 14 (0,8%) 13 (0,7%) 13 (0,7%) 
No da ta 21 (1 ,2%) 38(2,1 %) 126 (7,1 %) 251 (14,1 %) 21 (1 ,2%) 
Table 3. Patients' self-assessment at control 
Parameter Visit 1 Visit 2 Visit 3 Last visit LOCF
visits and rating according to CGI-i (LOCF vs. 
admission, p < 0.001) 	 Very much improved 
Much improved 
Minimally improved 
No change 
MinimaUy worse 
Much worse 
Very much worse 
N =1778 
No da ta 
61 (3.4% ) 

350 (19.7%) 

856 (48.1 %) 

424 (23.8 %) 

33 (1.9%) 

13 (0.7%) 

4 (0.2%) 

199 (11.2%) 
745 (41.9%) 
581 (32.7 %) 
103 (5.8%) 
15 (0.8%) 
13 (0.7 %) 
3 (0.2%) 
518 (29.1%) 556 (31.3%) 
722 (40.6 %) 795 (44.7%) 
218 (12.3%) 272 (15.3%) 
57 (3.2%) 87 (4.9 %) 
9 (0.5 %) 12 (0.7%) 
8(0.4%) 14 (0.8%) 
1 (0.1 %) 5 (0.3%) 
1741 (97.9%) 1659 (93.3%) 1533 (86.2%) 1741 (97.9%) 
37 (2.1 %) 119 (6.7 %) 245 (13.8%) 37 (2.1%) 
had similar problems before; in 1,073 patients (60.3%) an or­
ganie eause had been excluded, whereas in 88 patients (4.9%) 
it was eonfirmed; 1,068 patients (60.1 %) reported psyehoso­
eial stress preeeding their problems, and 850 (47.8%) feit they 
were related to external events or eireumstanees. 64 patients 
(3.6%) admitted an addietion in the past , and 51 patients 
(2.9%) at the time of admission. The addietions reported 
ranged from alcohol (n = 72, 4%), pharmaeeutieals (n = 17, 
1 %), drugs (n = 5, 0.3% ) to those 'not speeified ' (n = 11, 
0.6%). 
The vast majority of the patients were diagnosed with de­
pressive episodes (F32.0-F33.9; n = 1,481; 83.3%); other diag­
noses eould be classified as neurotie, stress-related and so­
matoform disorders, i.e. anxiety (F40-F48: n = 137; 7.71 %), 
psyehovegetative syndrome (F45.3: n = 123; 6.9%), exhaus­
tion (F43-F43.9: n = 107; 6.0%), ete. Only 2 patients (0.1 %) 
were diagnosed with bipolar disorder (F31.9). Considering the 
highest ICD-derived subseore, depression predominated in 
892 patients (50.17 % ), while anxiety predominated in 735 
(41.34%) and somatie symptoms of anxiety/depression in 151 
patients (8.49%). 
The treatments preseribed were either Helarium® tablets 
(n = 452; 25.42%) or Helarium-425® eapsules (n = 1,319; 
74.18% ; no data: n = 7; 0.39%). The mean daily dose was 
822.5 ± 205.4 mg dry ethanolie Hyperieum extraet at admis­
sion (range 425-1,700 mg) and 754.4 ± 231.1 mg at the last 
visit. The most eommonly preseribed dosage sehedules were 
an intake twiee or three times daily (58.6% or 27.1 % of the 
patients, respeetively). These eontinued to be the favored 
sehedules as the trial went on. 
In addition to the Hyperieum treatment, 492 patients 
(27.7%) reeeived supportive psyehotherapy (n = 335; 18.8%), 
speeifie psyehotherapy (n = 56; 3.1 %), gymnasties (n = 35; 2%), 
ete. 
At admission , 145 (8.16% ) of the patients diseontinued 
their psyehotropie medieation, mostly antidepressants, anxio­
lyties, and hypnoties/sedatives. During the study, 134 patients 
reeeived 194 new preseriptions, predominantly hypnoties/sed­
atives, antidepressants, and anxiolyties. Noteworthy is the low 
proportion of patients medieated at admission , and the very 
limited number of eo-preseriptions whieh might refleet the 
mostly mild to moderate nature of the depressive disorders 
treated. 
Outcomes 
Clinical Global Impression 
The proportion of patients deseribed as 'normal' to 'mildly ill' 
inereased from 21.6% at admission to 72.4% at the last visit 
(visit 3, last observation earried forward - LOCF. table 2). 
Consistently, the proportion of those rated as 'moderately ill' 
or 'worse' deereased from 76.6% to 26.5%. Regarding the 
CGI-i, at the last visit (LOCF) 77 % of the patients were re­
ported to have (very) mueh improved. That was eonsistent 
with the patients' self-assessments aeeording to whieh 76% 
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Fig. 1. Mean ICD·10 derived subscores for 
depression . anxiety. and somatic symptoms -5 
(10 items each; scores 0-40) and somatoform 
disorders (5 items; scores 0-20). 
had improved (very) much (table 3). In all of these seal es the 
improvement was progressive and largest at the end of the 
trial. Comparing the ratings at the last visit (LOCF) with 
those at admission, improvements were highly significant in 
all three of these variables. 
[CD-lO Derived Scores 
The ICD-10 derived scores are regarded as me an va lues of 
the 4 subscores over time and as mean scores of the individual 
symptoms at admission and at the last visit (patients 'on treat­
ment'; fig. 1). 
After 4 weeks of treatment (visit 1), the mean total sum 
score had diminished significantly by 23.6%, without major 
differences between subscores (depression: -23.2%, anxiety: 
-24.9%, somatic symptoms of anxiety/depression: -21.8%, so­
matoform disorder: -24.8%; all p < 0.001). The reduction had 
continued significantly at the 2nd control visit after approxi­
mately 8 weeks of treatment; the total sum score had dimin­
ished by 46% compared to admission (depression: -46.6%, 
anxiety: -47%, somatic symptoms of anxiety/depression: 
-42.2%, somatoform disorder: -47%; all p < 0.001). At the 
last control visit, the mean total sum score had dropped sig­
nificantly by 63.1 % with some differences between subscores, 
i.e. the somatic symptoms related to anxiety/depression di­
minished less, i.e. by 55.7% (depression: -63.6%, anxiety: 
-62.6%, somatoform disorder: -66.9%; all p < 0.001) (fig. 2). 
Comparing the mean ICD-lO derived scores at admission 
and at visit 3 there is a homogeneous reduction of the indi­
vidual symptoms rated. Noteworthy is the low score of sui­
cidal thoughts already at admission, which seems indicative of 
the mostly mild to moderate nature of the depressive disor­
ders treated. 
Visual Analogue Seale (VAS) 
The patients were administered a V AS at each visit. The 
steady and significant drop of its mean value indicates an im­
proved subjective well-being of the patients. The difference 
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was highly significant, i.e. p < 0.001, but there were no data of 
33.4% of the patients. 
Factors Affecting Outcome 
Higher age, longer duration of the disorder (frequently asso­
ciated with earlier episodes) and the ICD-lO derived sum 
score at admission were associated in stepwise regression 
analyses with a higher, i.e. worse, ICD-lO derived sum score 
at the final visit (constant: -5.95, ± 95% CI 3.98, P = 0.003; 
age: coefficient 0.08, ± 95% CI 0.05, P < 0.001; duration: coef­
ficient 0.08, ± 95% CI 0.05, P = 0.001; ICD sum score at ad­
mission: coefficient 0.27, ± 95% CI 0.08, P < 0.001). Higher 
doses at admission were also associated with poorer outcomes 
(p = 0.037), probably reflecting more serious conditions at the 
outset. Comparing the improvements of the highest and low­
est quintiles of the study sampie by ICD-10 derived sum 
scores at admission , age or duration of disorder (variable: 
CGI-i at last visit LOCF), the ICD-10 derived sum score had 
no influence on the outcome. Lower age and shorter duration 
of disorder were associated significantly more often with 
being rated as 'very much improved'. 
Safety 
Patients rated the tolerance as 'very good' (n = 1,172; 
65.92%) , 'good' (n = 500; 28.12%) and 'moderate, poor or 
very poor' (n = 27; 1.51 % ; assessed: n = 1,721 ; 96.79%). The 
frequency of ADR was 3.54% (any event counted once per 
patient; table 4) and decreased from 2.9% at the first control 
visit to 1.2% at visit 2, and 1 % at visit 3. The only ADR re­
ported by >1% of the patients were gastrointestinal troubles 
and tiredness; followed by photosensibilization and restless­
ness (0.7% each). 
In terms of adverse events, 5 patients (0.3%) were hospital­
ized due to psychiatrie reasons and 1 due to an aggravation of 
a previously known colitis ulcerosa before the first control 
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Fig. 2. Mean ICD-10 derived symptom scores for rating of the severity of adepression, b anxiety, c somatic symptoms related to depression or anxi­
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Table 4. Summary of ADRs recorded at each 
ADR 	 Visit 1 Visit2 Vis.it 3 Total
visit and total 
Gastrointestinal troubles 16 (0.9%) 5 (0.28%) 4 (0.22%) 20 (1.12%) 

Tiredness 12 (0.67%) 8(0.45%) 7 (0.39%) 19 (1.07%) 

Photosensibilization 11 (0.62%) 3(0.17%) 2 (0.11 %) 11 (0.62%) 

Restlessness 9 (0.51 %) 2(0.11%) 3(0.17%) 10 (0.56%) 

Allergic skin reaction 2(0.1 1%) 2 (0.11 %) 1 (0.06%) 3 (0.17%) 

Appetite increased 2 (0.11 %) 0(0%) 0(0%) 2 (0.11%) 

Dizziness, beadache 1 (0.06%) 1 (0.06%) 1 (0.06%) 1 (0.06%) 

Constipated 1 (0.06%) 0(0%) 0(0%) 1 (0.06%) 

Polyuria 1 (0.06%) 0(0%) 0(0%) 1 (0.06%) 

Acroparesthesias 1 (0.06%) 0(0%) 0(0%) 1 (0.06%) 

Difficu1ty swallowing capsule 1 (0.06%) 0(0%) 0(0%) 1 (0.06%) 

Vertigo 0(0%) 1 (0.06%) 0(0%) 1 (0.06%) 

ADRs,n 57 22 18 71 

Patients with ADRs, n 52 (2.92%) 21 (1.18%) 17 (0.96%) 63 (3.54%) 

cephalgia 
visit. There were no deaths reported in this study. A house- treatment and was withdrawn from the trial . She received no 
wife aged 57 taking Helarium 425® was reported to have se- other medication at the time and no other data of interest 
verely increased photosensitivity during the first month of were reported . Another female, aged 67years, also withdrew 
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from the trial due to increased photosensitivity and a male pa­
tient, aged 63 years, withdrew due to a 'side effect' not speci­
fied further. 
The frequency of ADRs was similar in patients who re­
ceived comedication , whether psychotropic or not. However, 
the number of these patients is relatively small (n =134). Cu­
taneous reactions, including increased photosensitivity, were 
reported more frequently in males (due to more exposure to 
sunlight?) whereas digestive troubles and tiredness were more 
frequent among female patients. 
Discussion 
The latest metaanalysis of RCTs found Hypericum prepara­
tions to be superior to placebo in patients with major depres­
sion, to be similarly effective and to have fewer side effects 
than standard antidepressants [22] . Yet, a trend for decreasing 
effect sizes over time in trials of St. John's wort was seen in 
another metaanalysis [23], suggesting that St. John's wort may 
be less effective in treating depression than previously thought. 
More recent trials - which include only patients with docu­
mented major depression or large proportions of patients who 
have suffered from their current depressive episode for >2 
years - may have excluded groups that are particularly respon­
sive to Hypericum extract [24] . Consistent with this observa­
tion, the strengths of the study presented he re is that it found a 
poorer outcome in patients with Ion ger duration of the disor­
der, higher age and - less consistently - a higher symptom 
score at admission. This increases our knowledge of the factors 
that affect the treatment response. These finding were also ob­
served in a large cohort of outpatients treated with selective 
serotonin reuptake inhibitors (SSRI) [25] . Furthermore, con­
sidering the highest ICD-derived subscore, depression pre­
vailed in half of the cases, anxiety prevailed in 41.3% of the 
cases and somatic symptoms of anxiety/depression were high­
est in 8.5% of the patients. This stratification had no relevant 
influence on the outcomes. However, these results somehow 
correspond with data on the comorbidity of depression and 
anxiety as well as with associations between somatic com­
plaints and depression and they could give an additional ra­
tional for the use of Hypericum [26,27]. While it would be pre­
mature to draw any conclusions concerning efficacy from these 
observation al findings, they may be of interest to genera te hy­
potheses for future trials with Hypericum, because a consistent 
and progressive reduction of these symptoms could be seen in 
the ICD-lO derived scores (anxiety, somatoform, and somatic 
symptoms). Yet, one has to be aware that placebo effects, the 
natural course of the disorder, and regression to the mean can 
result in high rates of good outcomes that may be misattrib­
uted to the specific treatment [28, 29]. 
Possible shortcomings of this study are that most of the pa­
tients inves tigated had only mild to moderate depression, thus 
the results cannot be extrapolated to patients with more se-
Hypericum for Depression in Outpatients 
vere depression. Yet, the patient group studied here corre­
sponds to a community-based population generally found in 
outpatient settings. Furthermore, although we found that the 
duration of depression correlated negatively with the duration 
of the disorder, this could not be analyzed in more detail due 
to a lack of data. Finally, the ICD-lO score used may seem 
unusual. Yet it was chosen in order to facilitate a transfer of 
the physicians' diagnoses in daily practice into diagnostic cat­
egories. In order to ensure correspondence with commonly 
used psychometric instruments, the ICD-derived scales were 
validated with the HAMDn and its subscores and correlated 
significantly. 
Although St. John's wort is generally weil tolerated in clini­
cal trials, increasing attention has been given to its tendency to 
compromise the effectivity of other medications (e.g., cy­
closporine, HIV protease inhibitors, oral contraceptives, dig­
oxin , warfarin, and theophylline) by inte ractions mediated 
through cytochrome P450 enzymes [30] and transport protein 
P-glycoproteins [31]. Thus, prescribers should beware of pos­
sible decreases in the systemic bioavailability of conventional 
drugs [32] especially with Hypericum extracts rich in hyper­
forin [33, 34]. In the study presented here, comprising a total 
of 1,778 patients , the frequency of adverse effects was low 
(3.54% of the patients), decreased over time and was similar in 
patients who received comedication, whether psychotropic or 
not. There were neither serious nor unexpected ADRs. This 
low incidence of ADRs with Helarium® is in line with formerly 
pubJished data on Hypericum preparations, especially Hyperi­
cum preparations not enriched in hyperforin [35]. 
Conclusions 
In this open observational study, the herbai preparation of 
Hypericum perforaturn was weil tolerated and no new or seri­
ous adverse effects were identified. In view of the limitations 
of the study design , it may be concluded that Hypericum per­
foraturn was a quite effective antidepressant for mild to mod­
erate depression. A positive treatment response was favored 
by a more recent onset of the disorder, lower age of the pa­
tients and, possibly, less severe symptoms at base line. 
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